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Multipotent mesenchymal stem or stromal cells (MSC) have
shown to improve outcome of acute renal injury models, but
whether MSC can delay renal failure in chronic kidney disease
is not known. We injected primary MSC or saline into mice
that lack the a3-chain of type IV collagen (COL4A3), a model
of chronic kidney disease with close similarities to human
Alport disease. Weekly injections of MSC from week 6 to 10 of
life prevented the loss of peritubular capillaries and reduced
markers of renal fibrosis, that is, interstitial volume, numbers
of smooth muscle actin-positive interstitial cells, and
interstitial collagen deposits as compared to saline-injected
COL4A3-deficient mice. However, renal function, that is,
blood urea nitrogen, creatinine levels, proteinuria as well as
survival of COL4A3-deficient mice were not affected by MSC
injections. Although MSC were found to localize to kidneys of
COL4A3-deficient mice after injection, differentiation into
renal cells was not detected. However, MSC expressed
growth factors, that is, vascular endothelial growth factor
(VEGF) and bone morphogenetic protein-7 under basal
culture conditions. In fact, VEGF mRNA levels were increased
in kidneys of MSC-injected COL4A3-deficient mice and MSC
supernatants enhance endothelial cell proliferation in vitro.
Thus, weekly injections with MSC prevent loss of peritubular
capillaries possibly owing to local production of growth
factors rather than by differentiation into renal cells. The
maintenance of interstitial vasculature is associated with less
interstitial fibrosis but, is insufficient to delay renal failure and
survival of COL4A3-deficient mice.
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Stem cells have been proposed as a new opportunity for the
treatment of many diseases. In view of ethical concerns
regarding the use of embryonic stem cells, adult stem cells,
for example, bone marrow-derived and fibroblast-like plastic-
adherent mesenchymal stem cells or their closely related
counterpart, multipotent mesenchymal stromal cells (MSCs),
may represent a valuable substitute.1 MSCs reside in the bone
marrow’s non-hematopoietic stromal compartment and can
be isolated using selection owing to plastic adherence.2 MSCs
produce growth factors and cytokines that support hemato-
poiesis in vivo and in vitro, but MSC can also differentiate
into a wide variety of cell lineages.3 In rodents, injections
with MSC have proven beneficial in either toxic or ischemic
tubular necrosis,4–6 ischemic limb, or heart disease.7,8 Less
well-defined bone marrow-derived cells reconstitute the
mesangium after mesangiolysis.9 However, the effects of
MSC observed in acute and potentially reversible models of
mesangial or tubular injury may not apply to chronic kidney
disease.10 In the fibrotic kidney, MSC could also promote
fibrogenesis-associated progression of tubulointerstitial da-
mage similar to what has been observed in obstructive
nephropathy or the fibrotic lung.11,12 To date, the effect of
MSCs on the progression of chronic kidney disease is
unknown.13 We addressed this question by preparing
primary murine MSCs that were injected into mice deficient
for the a3-chain of type IV collagen (COL4A3). These mice
are characterized by an abnormal assembly of glomerular
basement membranes similar to human Alport disease.14,15
COL4A3-deficient mice represent a model for chronic kidney
disease associated with interstitial fibrosis and uremia-related
death around 10 weeks of age.14,16 We show that injected
MSC localize to kidneys of COL4A3-deficient mice, but
remain within peritubular capillaries and do not transdifferen-
tiate into renal cells. MSCs prevent the loss of peritubular
capillaries and interstitial fibrosis, which, however, is not
associated with prolonged survival of COL4A3-deficient
mice.
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RESULTS
Distribution and fate of intravenously injected MSC in
COL4A3-deficient mice
In order to determine their intrarenal distribution MSCs
were labeled with a red fluorescent dye and kidneys of 6- and
9.3-week-old COL4A3-deficient mice were obtained 3 days
after intravenous injection. Labeled MSCs were found to
locate to the renal cortex outside the tubular compartment,
which was apparent by costaining renal epithelial cells for
cytokeratin and laminin for which costaining with MSCs was
not observed (Figure 1a and b). Staining renal endothelial
cells with an MECA-32-specific antibody revealed that MSCs
localized within peritubular capillaries (Figure 1c). MSCs
neither colocalized with MECA-32 (Figure 1c) nor were
MSCs detected in the glomeruli of COL4A3-deficient mice
(not shown). Costaining with a Ki-67-specific antibody
addressed the question of MSC proliferation in kidneys of
COL4A3-deficient mice. The intrarenal MSC (10%) stained
positive for Ki-67 (Figure 1d). Next, we intended to assess the
fate of MSCs that distribute to peritubular capillaries. For
this purpose, fluorescently labeled MSCs were injected at
various intervals before being killing at 9.3 weeks of age. Two
hours after injection, 11.072.1 MSCs were detected per high
power field in kidneys of COL4A3-deficient mice (Figure 2).
Three and 7 days after injection, the number of MSCs in
peritubular capillaries had declined to 6.771.6 and 4.471.2
MSCs/high power field, respectively (Figure 2, n¼ 6–8/
group). MSCs injected into 6-week-old COL4A3-deficient
mice were detected at very low numbers in the renal
interstitium, indicating that MSC recruitment increases in
more advanced stages of kidney disease.
MSCs prevent interstitial fibrosis in COL4A3-deficient mice
We hypothesized that recruitment of injected MSCs to the
kidney would modulate renal pathology of COL4A3-deficient
mice. Thus, COL4A3-deficient mice were killed at the age of
9.3 weeks after 4 weekly injections of MSCs or saline for
collection of renal tissue.
Glomerular injury. Saline-injected COL4A3-deficient mice
had diffuse glomerulosclerosis as compared to age-matched
wild-type control mice (Figure 3, Table 1). Glomerulo-
sclerosis was characterized by segmental or global increase of
glomerular matrix, adhesions to Bowman’s capsule, or
crescent formation. Injections with MSC did not affect the
percentage of either segmental or global glomerulosclerosis
or the number of Mac2-positive glomerular macrophages in
COL4A3-deficient mice (Table 1, Figure 3).
Interstitial fibrosis. COL4A3-deficient mice showed dif-
fuse interstitial fibrosis when compared to wild-type mice
(Figure 4). This was evident from quantitative morphometry,
as saline-injected COL4A3-deficient mice showed an increase
of the respective indices for interstitial volume, interstitial
collagen, and smooth muscle actin-positive area as compared
to wild-type mice (Figure 4, Table 1). MSCs significantly
reduced all these markers compared to vehicle-treated
COL4A3-deficient mice (Figure 4). In saline-injected
COL4A3-deficient mice interstitial fibrosis was associated
with markedly reduced numbers of peritubular capillary
cross-sections. MSC injection partially restored the density of
peritubular capillaries as compared to wild-type mice
(Table 1, Figure 3). Interstitial fibrosis in COL4A3-deficient
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Figure 1 | Distribution of injected MSC in COL4A3-deficient mice.
MSCs were labeled with a red fluorescent dye and intravenously
injected into 9.3-week-old COL4A3-deficient mice. Three days later,
tissues were obtained and frozen sections were subjected to
microscopy. (a) Costaining of renal sections for cytokeratin with an
FITC-labeled antibody stains tubular epithelial cells in green. DAPI
4;6-diamidine-21-phenylindolc dihydrochloride stains cell nuclei in
blue. Red-labeled MSCs did not colocalize with tubular epithelial cells
(original magnification  200). (b) Costaining of renal sections with
an FITC-labeled laminin antibody stains tubular, glomerular, and
vascular basement membranes in green. DAPI stains cell nuclei in
blue. Red-labeled MSC did not localize inside tubular cross sections
(*), but rather to peritubular vascular cross sections (original
magnification  200). (c) Costaining of renal sections with an
FITC-labeled MECA-32 antibody stains vascular endothelial cells in
green. Red-labeled MSC localize within the lumen of peritubular
capillaries (white arrows, original magnification  400). (d) Costaining
of renal sections for Ki-67 with an FITC-labeled antibody stains nuclei
of proliferating cells in green. DAPI stains cell nuclei in blue. Only
single red-labeled MSC show costaining for the proliferation marker
(original magnification  400). Images are representative for five
individual mice.
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Figure 2 | Interstitial MSC after intravenous injection in COL4A3-
deficient mice. Numbers of interstitial MSCs at various intervals after
intravenous injection in kidneys of 9.3-week-old COL4A3-deficient
mice (n¼ 6–8 for each time point). Values represent means7s.e.m.
*Po0.05 vs 2 h.
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mice was associated with an increased number of interstitial
Mac2-positive macrophages when compared to saline-treated
mice. MSC injection did not affect the numbers of interstitial
Mac2-positive macrophages as compared to saline-treated
COL4A3-deficient mice (Figure 3, Table 1).
Renal function. COL4A3-deficient mice had proteinuria
consistent with their diffuse glomerulosclerotic lesions
(Figure 5). Weekly injections with MSC from week 6 to 9
did not affect protein/creatinine ratios in urines compared to
saline-treated mice at week 9 (Figure 5). No statistical
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Figure 3 | Renal histopathology in COL4A3-deficient mice. Renal sections of wild-type and COL4A3-deficient mice were stained with
periodic acid-Schiff solution or with antibodies for the indicated markers as described in methods. Images are representative for eight to
10 mice in each group. For quantification see Table 1, original magnification  100–200. Dotted circles indicate the glomeruli.
Table 1 | Serum, urinary, and histological findings in collagen4A3-deficient mice
Wild type (n=6) Collagen4A3/+saline (n=10) Collagen4A3/+MSC (n=10)
Renal function
Blood urea nitrogen (mg/dl) 32.375.2 107.0783.6* 131.6757.7*
Serum creatinine (mg/dl) 0.4070.07 0.7770.45 0.8270.43*
Glomerulosclerosis score
0 (no lesion in %) 9173 375* 374*
1 (1–24%) 971 1372 1577*
2 (25–49%) 070 2273* 2675*
3 (50–74%) 070 2975* 2975*
4 (75–100%) 070 33711* 29711*
Cellular response (cells/glomeruli or high-power field)
Glom. Mac2+ 0.170.1 1.270.7* 1.170.6*
Interst. Mac2+ 0.970.5 14.373.8* 11.575.8*
Smooth muscle actin+ (%/high-power field) 0.670.6 8.273.1* 2.971.4*#
Peritubular capillaries (capillary cross sections/hpf)
MECA-32+ 115.1713.3 42.878.4* 79.5712.0*,#
MSC, mesenchymal stromal cells; HPF, high-power field.
Values represent mean7s.e.m.
*Po0.05 vs wild type.
#Po0.05 MSC vs saline.
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significant differences were noted in blood urea nitrogen in
saline- and MSC-treated COL4A3-deficient mice at week 9
(Table 1). Although serum creatinine levels determined by
the Jaffe method can overestimate creatinine levels in mice,17
no significant difference was detected in serum creatinine
levels in saline- and MSC-treated COL4A3-deficient mice at
week 9 (Table 1). These data show that MSCs can prevent loss
of peritubular capillaries and interstitial fibrosis, but not
glomerulosclerosis, proteinuria, and renal failure in COL4A3-
deficient mice.
Survival of COL4A3-deficient mice injected with MSC
Next, we studied the effects of MSC injection on survival of
COL4A3-deficient mice treated with either MSC or saline.
Saline-treated COL4A3-deficient mice showed a mean
survival of 75 days (95% confidence interval 68–82 days),
whereas weekly injections with MSC from week 6 to 9 had a
mean survival of 84 days (95% confidence interval 76–93
days). Kaplan–Meier analysis using log-rank two-tailed
testing revealed a P¼ 0.16, indicating that MSC injections
did not significantly affect survival of COL4A3-deficient
mice (Figure 6). Mortality of COL4A3-deficient mice was
likely to be related to uremic death as within the last week
of life the physical activity of COL4A3-deficient mice
continuously declined until death as noted in previous
studies.16,18 Wild-type control mice remained healthy until
the end of the study.
MSC express basal levels of VEGF and BMP-7
As we did not observe MSC differentiation into renal cells in
kidneys of COL4A3-deficient mice, paracrine secretion of
mediators, for example, cytokines or growth factors, may
represent another mechanism how MSC cells modulate local
tissue injury. For example, small amounts of bone morpho-
genetic protein (BMP)-7 and vascular endothelial growth
factor (VEGF) have been shown to have strong modulatory
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Figure 4 | Extracellular matrix and fibrosis in kidneys of COL4A3-deficient mice. (a and b) Renal sections of wild-type and COL4A3-
deficient mice were stained with silver (a) Images illustrate representative sections of kidneys from the respective groups at week 9.3 of age
(original magnification  100). (b) Morphometric analysis of silver-stained cortical renal sections was performed as described in Materials and
Methods. Values represent means7s.e.m. of the respective index from nine to 10 mice in each group. *Po0.0001 vs wild-type mice; #Po0.005
vs saline-injected COL4A3-deficient mice.
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Figure 5 | Proteinuria in COL4A3-deficient mice. Urinary protein/
creatinine ratios were determined from urine samples taken at
weekly intervals from saline- (&) or MSC-injected COL4A3-deficient
mice (’) and saline-injected wild-type mice (B). Values represent
means from 10 to 17 mice in each group. P-values for comparison of
groups are as indicated.
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Figure 6 | Survival of COL4A3-deficient mice. Groups of COL4A3-
deficient mice were injected with either MSCs or saline alone as
indicated (n¼ 9–10). Survival is illustrated as Kaplan–Meier curve.
124 Kidney International (2006) 70, 121–129
o r i g i n a l a r t i c l e V Ninichuk et al.: Mesenchymal stem cells in chronic kidney disease
effects on the progression of renal injury.19,20 In fact, MSCs
cultured for 24 h either with or without fetal calf serum
expressed significant levels of growth factors, that is, VEGF
and BMP-7 mRNA (Figure 7a). Next, we hypothesized that
the microenvironment of a chronically injured kidney may
modulate MSC gene expression and growth factor produc-
tion. In order to address this issue, we examined the gene
expression profile of MSCs cultured without serum using 430
Affymetrix gene array. MSCs were incubated with super-
natants of cells prepared from kidneys of either 9.3-week-old
healthy wild-type mice or diseased COL4A3-deficient mice
(n¼ 3). After 12 h of incubation, MSCs were harvested and
total RNA was prepared for gene array analysis. The analysis
intended to identify genes differentially expressed by MSCs
exposed to either a nephritic or a non-nephritic cytokine
environment. The correlation coefficient between the two
culture conditions for the expression of each gene was greater
than 0.975 (Figure 7b). Comparison of the gene expression
profiles of MSCs exposed to healthy or diseased kidney
supernatants showed that no genes were statistically sig-
nificantly differentially expressed (Figure 8). Thus, 12 h
exposure of MSCs to supernatants of kidney cells prepared
from COL43A-deficient mice does not modulate the gene
expression profile of MSC.
Expression of VEGF and BMP-7 in kidneys
of COL4A3-deficient mice
In order to test whether kidneys of MSC-treated COL4A3-
deficient mice show higher expression levels of the a
forementioned growth factors, we performed real-time
reverse transcription-polymerase chain reaction (RT-PCR)
for mRNAs of VEGF and BMP-7 on total RNA isolates from
COL4A3-deficient mice that had been injected with MSCs or
saline 7 days before being killing. MSC-injected kidneys
expressed twofold higher levels of VEGF mRNA compared to
saline-injected COL4A3-deficient mice; however, this did not
reach statistical significance (Figure 8). BMP-7 mRNA levels
were comparable in both groups. These data suggest that
MSCs prevent the loss of peritubular vasculature in
association with increased VEGF levels in kidneys of
COL4A3-deficient mice.
Soluble factors released by MSCs induce endothelial cell
proliferation
The observation that MSC injection maintains the peri-
tubular capillary network in COL4A3-deficient mice can
either be explained by enhanced endothelial cell proliferation
or reduced endothelial cell death. To address this question,
we coincubated a murine endothelial cell line with super-
natants of either MSC, cultured under starving conditions, or
VEGF under serum-free conditions. MSCs and VEGFs both
markedly increased endothelial cell proliferation (Figure 9).
In addition, we asked whether MSC supernatants effects
improve EC survival under serum-free culture conditions.
Using identical culture conditions, endothelial cell death was
determined by costaining for propidium iodine and annexin
5. MSC and tubular cell supernatants both did not affect the
percentage of apoptotic or necrotic endothelial cells after 24 h
of incubation (data not shown). These data suggest that
soluble factors released by MSCs increase endothelial cell
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Figure 7 | Gene expression analysis of cultured MSC. (a) Primary
MSCs were cultured in standard medium with (black bars) and
without (white bars) fetal calf serum. Expression of VEGF and
BMP-7 mRNA was determined by real-time RT PCR as described in
Materials and Methods. Data are expressed as ratio to respective
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA
expression. (b) Gene array analysis of cultured MSCs exposed to
healthy or nephritic kidney cell suspensions. MSCs were incubated
with supernatants of renal cells prepared from either 9.3-week-old
wild-type mice or COL4A3-deficient mice (n¼ 3). After 12 h of
incubation, MSCs were harvested and total RNA was prepared for
gene array analysis as described in Materials and Methods. Statistical
analysis was performed with the significance analysis of microarrays
(SAM) tool as implemented in the Bioconductor Siggenes package.
Circles correspond to individual genes. Y-axis: Observed differential
gene expression score (modified t-statistic) derived from the
comparison of MSC exposed to healthy or nephritic kidney cell
supernatant, X-axis: Expected differential gene expression score
derived from full permutations of the class labels. Solid line:
Observed¼ expected differential gene expression score; dashed
line: significance threshold. Differentially expressed genes can be
identified by their position away from the solid diagonal.
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Figure 8 | Expression of VEGF and BMP-7 in kidneys of
COL4A3-deficient mice. Expression of mRNA was determined by
real-time RT-PCR using total renal RNA from 10 mice in each group.
mRNA levels for saline- and MSC-injected COL4A3-deficient mice are
expressed as mean7s.e.m. of the ratio to respective glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRNA expression of each
kidney. Ratios of saline-treated COL4A3-deficient mice are set as 1.
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proliferation but do not prevent endothelial cells death under
serum-free culture conditions.
Discussion
Injection of cultured MSCs can have beneficial effects on
experimental models of acute kidney disease,4–6 but their
effects on chronic kidney disease is unknown. We used
COL4A3-deficient mice as a model of chronic kidney disease
associated with interstitial fibrosis and renal failure.
MSCs prevent interstitial fibrosis, but do not prolong survival
of COL4A3-deficient mice
Morphometry revealed that MSC injections reduced inter-
stitial volume in COL4A3-deficient mice. In adult COL4A3-
deficient mice, the interstitial compartment consists of the
peritubular vasculature, myofibroblasts, interstitial matrix,
and immune cell infiltrates.16 Numbers of interstitial
macrophages were comparable in both groups. By contrast,
collagen deposits and the smooth muscle actin-positive area
were reduced in the renal interstitium of MSC- vs saline-
injected COL4A3-deficient mice. Thus, the reduced inter-
stitial volume in MSC-injected COL4A3-deficient mice
relates to a decreased number of interstitial myofibroblasts
and collagen deposits. Renal fibroblast proliferation and
matrix production are driven by renal ischemia.21 In fact, the
numbers of peritubular capillaries increased with MSC
injections as determined by immunostaining for the
endothelial cell marker MECA32. MSC have shown to
enhance neoangiogenesis and tissue repair in ischemic
skeletal muscle,7 myocardium,8,22 and kidney.6 Thus, the
proangiogenic effects of injected MSC may prevent loss of
peritubular capillaries and subsequent fibroblast proliferation
and matrix production in the renal interstitium of COL4A3-
deficient mice. Although the extent of interstitial fibrosis is
considered to be a major factor of progression in chronic
kidney disease, MSC-related reduction of interstitial fibrosis
did not delay renal failure in COL4A3-deficient mice. These
data are consistent with a recent study that found progression
to uremic death of COL4A3-deficient mice to be independent
of the extent of interstitial fibrosis.23 In this study, blockade
of tumor growth factor (TGF)-b reduced myofibroblast
proliferation and interstitial matrix deposition, which did not
result in prolonged survival of COL4A3-deficient mice.
Obviously, in COL4A3-deficient mice, interstitial fibrosis is
a marker of chronic kidney disease, but progressive loss of
renal function is driven by other factors. For example,
previous studies have identified integrin-a1b1, angiotensin II,
vasopeptidase, and chemokine receptor CCR1-dependent
interstitial macrophage recruitment as factors that contribute
to the progression of kidney disease in COL4A3-deficient
mice.18,23–25 Given the low number of MSCs recruiting to the
renal interstitium of 6-week-old COL4A3-deficient mice, it is
rather unlikely that an earlier onset of MSC injections may
have shown different results. Thus, our data argue for a
limited role of MSC injections in chronic kidney disease.
MSCs neither differentiate into tubular cells nor change their
gene expression profile in a chronically diseased kidney
microenvironment
The MSCs we used in our experiments have the capacity to
differentiate into multiple cell lineages, for example, skeletal
muscle cells, and hematopoietic cells.7,26 However, when
MSCs were injected into mice after ligation of the femoral
artery neoangiogenesis was markedly enhanced in the
absence of MSC differentiation into for example, endothelial
cells.7 Data from two different models of acute tubular
necrosis suggested that injected MSCs contribute to tubular
regeneration by differentiation into tubular epithelial cells.4,5
Our results show that MSCs do not differentiate into renal
cells in kidneys of COL4A3-deficient mice. MSCs were found
at considerable numbers within peritubular capillaries, but
not in the interstitial, tubular, or glomerular compartment.
The latter may relate to the lack of chemokine receptor CCR5
in MSC, which is required for the recruitment of leukocytes
to glomeruli and transendothelial diapedesis.27 In fact,
differentiation into tubular epithelial cells or interstitial cells
would require that MSC migrate from the intravascular into
the tubular or interstitial compartment of the kidney.
However, MSCs remained up to 7 days within peritubular
capillaries. Furthermore, their intravascular distribution and
their lack of MECA-32 expression argue against differentia-
tion of MSCs into endothelial cells of peritubular capillaries.
This finding is consistent with a recent study that injected
primary MSCs into rats with ischemic acute tubular
necrosis.6 Within 3 days after administration, none of the
intrarenal MSCs had differentiated into a tubular or
endothelial cell phenotype. Two recently published studies
using either Y-chromosome- or GFP-transgenic-based detec-
tion systems also failed to detect stem cell differentiation into
tubular cells as a repair mechanism in ischemic tubular
injury.28,29 In view of the studies reported from Morigi and
Herrera, the data regarding stem cell differentiation in kidney
disease are currently under debate.30
Obviously, MSCs can modulate tissue injury through
different mechanisms, for example, the production of growth
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Figure 9 | Proliferation of cultured renal endothelial cells. Murine
renal endothelial cells were incubated with supernatants of either
MSC (1:5) or VEGF in the medium (20 ng/ml) for 24 h. Proliferation was
assessed using CellTiter 96 Proliferation Assay. The optical density
was measured at 620 nm. Results are from one of the two
comparable experiments each performed in duplicate.
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factors. Togel et al.6 reported that 24 h after ischemic injury
renal mRNA levels of growth factors, that is, basic fibroblast
growth factor, VEGF, TGF-a, and Bcl-2 were upregulated in
kidneys of MSC-injected mice. We determined mRNA levels
of VEGF and BMP-7 in kidneys of 9.3-week-old COL4A3-
deficient mice. We found small increases of VEGF mRNA
levels in MSC compared to the saline-injected COL4A3-
deficient mice. Cultured MSCs showed basal expression of
VEGF and BMP-7, which was not affected by exposing MSCs
to the cytokine environment of diseased COL4A3-deficient
mice. These data suggest that injected MSCs secrete growth
factors into the renal interstitium of COL4A3-deficient mice.
In fact, MSC supernatants increase the proliferation of
cultured endothelial cells under serum-free conditions. For
example, VEGF, a proangiogenic factor protects the loss of
peritubular vasculature in chronic kidney disease.31 Admin-
istration of VEGF in the remnant kidney model increased
endothelial cell proliferation in peritubular capillaries and
reduced interstitial fibrosis.19 Accordingly, increased VEGF
mRNA levels were associated with increased numbers of
peritubular capillaries in MSC-injected COL4A3-deficient
mice. An additional role may have BMP-7 that is released by
MSCs. BMP-7 is a member of the TGF-b superfamily with
proven antifibrotic effects in models of chronic kidney
disease.20 For example, exogenous BMP-7 improved inter-
stitial fibrosis and tubular injury in mice with nephrotoxic
serum nephritis.32 However, we were unable to detect a
significant increase in renal BMP-7 mRNA levels associated
with MSC injection in COL4A3-deficient mice, which may
also relate to the low number of intrarenal MSCs 1 week after
the last MSC injection. Together, these data argue in favor of
MSC basal expression of growth factors that prevent loss of
peritubular vasculature and interstitial fibrosis in COL4A3-
deficient mice with Alport disease.
In summary, in COL4A3-deficient mice injected MSCs
distribute to peritubular capillaries but do not differentiate
into renal cells and almost completely disappear from the
kidney within a period of 7 days. Weekly MSC injections
prevent the loss of peritubular capillaries and interstitial
fibrosis in COL4A3-deficient mice, potentially owing to their
basal secretion of proangiogenic factors such as VEGF.
However, these effects are insufficient to delay renal failure in
COL4A3-deficient mice. As loss of renal function is
independent of interstitial fibrosis in COL4A3-deficient mice,
interstitial fibrosis may rather be a marker than a factor for
progression of chronic kidney disease.
MATERIALS AND METHODS
Preparation of bone marrow-derived MSCs
MSCs were prepared from the bone marrow of female mice as
described previously for peripheral blood-derived and fibroblast-
like, plastic-adherent cells.7,26 Briefly, the murine femur was rinsed
and mononuclear cells were cultured in Dulbecco’s modified Eagle’s
medium, supplemented with 10% fetal calf serum in standard tissue
cell culture dishes until an adherent and confluent cell layer was
established. Fibroblast-like and plastic-adherent cells were carefully
removed by ethylenediaminetetraacetic acid–trypsin digestion and
characterized at different culture passages by the surface expression
of a standard antibody panel in flow cytometry. According to a
recent preposition on the nomenclature for MSCs,2 the appropriate
term for these cells would be multipotent mesenchymal stromal cells
(MSCs), although true stem cell features for these cells cannot be
excluded at present. The primary MSCs between passages 4 and 6 in
culture were exclusively CD14, CD29þ , CD34, CD45, CD73þ ,
CD105, and major histocompatibility complex class II, like other
already published MSC-type cell lines.7,26 Some preparations of
MSCs were labeled with PKH26 (Red Fluorescent Cell Linker Kit,
Sigma-Aldrich Chemicals, Steinheim, Germany). Labeling efficacy
was assessed by flow cytometry to be 497%. Viability assessed by
Trypan blue exclusion was 490%. For in vitro studies, MSCs were
cultured without fetal calf serum for 24 h before use.
Animal studies
COL4A3-deficient mice on a 129/SvJ genetic background were bred
under specific-pathogen-free housing conditions as described.18 The
genotype of each mouse was confirmed by PCR using genomic DNA
extracted from tail tips. COL4A3-deficient mice develop glomerulo-
sclerosis and renal fibrosis and progress to uremia-related death at
about 10 weeks of age.16 At 6 weeks of age, COL4A3-deficient mice
were divided into two groups that received tail vein injections of
either 1 106 MSC in 200 ml isotonic saline or saline only at weekly
intervals. Treatment was continued until death for assessment of
survival or until day 66 of age (9.3 weeks) in a subgroup of mice that
were killed for histopathological evaluation. Urine samples were
obtained at weekly intervals and analyzed for protein/creatinine
ratios using an automatic autoanalyzer (Integra 800, Roche
Diagnostics, Germany) as described.24 Blood was drawn from the
retro-orbital sinus under general anesthesia before being killing.
Serum was analyzed for creatinine (Jaffe method) and blood urea
nitrogen using an automatic analyzer as above. In order to assess the
organ distribution injected MSC groups of 6- and 9.3-week-old
COL4A3-deficient mice were killed at various intervals after
injection with MSCs that had been labeled with PKH26 (Red
Fluorescent Cell Linker Kit, Sigma-Aldrich Chemicals, Steinheim,
Germany). Labeling efficacy was assessed by flow cytometry before
injection.
Histopathological evaluation
Renal tissue was obtained after 3 days, snap frozen, and prepared for
fluorescence microscopy. Costaining on frozen sections was
performed using the following primary and secondary antibodies:
mouse anti-cytokeratin 18 (Chemicon International, Hampshire,
UK, clone RGE53, 1:50) with a fluorescein isothiocyanate (FITC)-
labeled anti-mouse immunoglobulin (Ig) G1 antibody for detection
(Dianova, Hamburg, Germany; clone H143.225.8, 1:100); rabbit
anti-laminin (Abcam, Cambridge, UK; 1:25) with an FITC-labeled
anti-rabbit IgG antibody for detection (Abcam; 1:50); rat anti-Ki-67
DAKO, Hamburg, Germany; (clone TEC-3, 1:25) with an FITC-
labeled anti-rat IgG antibody for detection (Linaris, Wertheim-
Bettingen, Germany; 1:50). From each mouse parts of the kidneys
were fixed in 10% formalin and embedded in paraffin. Sections
(2mm) were stained with periodic acid-Schiff reagent or silver
following the instructions of the supplier (Bio-Optica, Milano,
Italy). Glomerular sclerotic lesions were assessed using a semi-
quantitative score by a blinded observer as follows: 0¼ no lesion;
1¼o25% sclerotic; 2¼ 25–49% sclerotic; 3¼ 50–74% sclerotic; and
4¼ 75–100% sclerotic, respectively. Fifteen glomeruli were analyzed
per section. The indices for interstitial volume and interstitial
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collagen deposition were determined as described previously.33 The
following primary antibodies were used for immunostaining as
described:24 rat anti-Mac-2 (Cedarlane, Ontario, Canada; macro-
phages, 1:50), anti-mMECA-32 (Iowa Hybridoma Bank, USA;
endothelial cells, 1:50), and mouse anti-smooth muscle actin
(DAKO, Carpinteria, CA, USA; myofibroblasts, clone 1A4, 1:100).
Interstitial cell counts were determined in 15 high power fields
by a blinded observer. For the quantification of the interstitial
smooth muscle actin-positive area digital pictures were analyzed as
described previously.24
Preparation and culture of renal cells
Kidneys from either COL4A3-deficient or wild-type mice were
manually dissected in a RPMI-1640 medium (GIBCO/Invitrogen,
Carlsbad, CA, USA) plus 10% fetal calf serum and cultured at 371C
for 48 h. Cell supernatants were obtained after centrifugation for
3 min at 1000 r.p.m. and added to cultured primary MSCs for 12 h at
371C. MSCs total RNA was extracted using a ‘Qiagen RNeasy Mini
kit’ (Qiagen Science, Germantown, MD, USA) according to the
protocol provided by the manufacturer.
In vitro studies with endothelial cells
Murine renal endothelial cells (GENC-clone 7) were cultured in
Dulbecco’s Modified Eagle’s Medium (GIBCO/Invitrogen) contain-
ing 10% fetal calf serum for 48 h at 371C.34 Cells were splitted and
kept in the medium without fetal calf serum 36 h prior incubation
with supernatants of either MSC (1:5) or VEGF in the medium
(20 ng/ml) for 24 h. MSCs used for that experiment were cultured
without fetal calf serum for 24 h. Proliferation of endothelial cells
was assessed using CellTiter 96 Proliferation Assay by adding 20 ml
CellTiter 96 Aqueous One Solution to each well and kept for 1.5 h at
371C (Promega, Mannheim, Germany). The optical density was
measured at 620 nm. Endothelial cell death was assessed by flow
cytometry after staining with propidium iodide and anti-Annexin
V–FITC (Annexin V–FITC apoptosis detection kit, BD Biosciences
Pharmingen, San Diego, CA, USA).
Real-time quantitative RT-PCR and Affimetrix chip microarray
profiling
For real-time RT-PCR kidney aliquots from each mouse or cultured
cells were snap frozen in liquid nitrogen and stored at 801C. RNA
preparation and real-time RT-PCR were performed as described.33
The following oligonucleotide primers (300 nM) and probes
(100 nM) were used: murine Vegf – forward, 50- GCTGTGCA
GGCTGCTGTAAC-30, reverse, 50-TGATGTTGCTCTCTGACGTGG-
30; internal fluorescence-labeled probe (FAM)–50-ATGAAGCCCTG
GAGTGCGTGCC-30; and murine Bmp7 – predeveloped reagent. All
primers and probes were obtained from PE Biosystems (Weiterstadt,
Germany).
Microarray experiments were carried out with total RNA from
cultured primary MSCs that had been incubated with supernatants
of kidney cell suspensions of either 9.3-week-old COL4A3-deficient
or wild-type mice for 12 h. Total RNA (6 mg) from three
independent preparations in each group were used for biotin-
labeled cRNA probe synthesis and hybridization of MOE 430Av2
arrays according to the Affymetrix Expresssion Analysis Technical
Manual (www.affymetrix.com). Triplicate arrays were scanned and
analyzed using the Affymetrix GeneChip Operating software (GCOS
1.0). Each array was checked for general assay quality (30-50 ratios
for glyceraldehyde-3-phosphate dehydrogenase and b-actin o1.1,
average background o75 fluorescence units, and scaling factors
within a two-fold range). Background corrected and normalized
expression measures from probe level data (cel-files) were obtained
by using the robust multichip average function implemented in
Bioconductor’s affy-package (http://www.bioconductor.org).35
Statistical analysis
Data are presented as mean7s.e.m. Paired Student’s t-test was used
for the comparison of groups. A value of Po0.05 was considered to
indicate statistical significance. Survival curves were compared by
Kaplan–Meier analysis using log-rank two-tailed testing. For
microarray data, multiple testing-adjusted statistical significance of
the probability for differential expression was assessed by the
permutation-based method of Tusher et al.36 as implemented in the
Bioconductor Siggenes package.
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